Guangdong Zhongsheng Pharmaceutical (002317.SZ) stated on the investor interaction platform on November 14th that, according to the "Guidelines for the Diagnosis and Treatment of Atopic Dermatitis in China (2020)", oral antihistamines are recommended for the auxiliary treatment of atopic dermatitis itching. The company's existing product, Chlorpheniramine Malate Oral Solution, is a pediatric formulation. The company is also actively focusing on the research and development, production, and sales of pediatric medications.
众生药业(002317.SZ)：现有产品富马酸氯马斯汀口服溶液为儿童专用剂型
Guangdong Zhongsheng Pharmaceutical (002317.SZ): the existing product Fumarate Chloramphenicol oral solution is a pediatric-specific dosage form.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated